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Abstract
Mass spectrometry (MS) has found numerous applications in life sciences. It has high accuracy, 
sensitivity and wide dynamic range in addition to medium- to high-throughput capabilities. These 
features make MS a superior platform for analysis of various biomolecules including proteins, 
lipids, nucleic acids and carbohydrates. Until recently, MS was applied for protein detection and 
characterization. During the last decade, however, MS has successfully been used for molecular 
diagnostics of microbial and viral infections with the most notable applications being 
identification of pathogens, genomic sequencing, mutation detection, DNA methylation analysis, 
tracking of transmissions, and characterization of genetic heterogeneity. These new developments 
vastly expand the MS application from experimental research to public health and clinical fields. 
Matching of molecular techniques with specific requirements of the major MS platforms has 
produced powerful technologies for molecular diagnostics, which will further benefit from 
coupling with computational tools for extracting clinical information from MS-derived data.
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Using mass spectrometry (MS) for the molecular diagnosis of infectious diseases is no 
longer novel [1]. Work on testing human metabolites and comparing the biochemical 
profiles of healthy and diseased individuals to detect disease was already underway in the 
1970s [2]. Interest towards the use of MS re-emerged when further advancements in the field 
took hold, in particular the introduction of MALDI [3] and ESI [4]. These gentle ionization 
technologies allowed for maintaining the integrity of nucleic acid (NA) oligomers and 
protein molecules with large molecular mass [3], or as laureate John Fenn said in his Nobel 
lecture, “the electrospray wings for molecular elephants” opened new opportunities for 
applying MS technology. The many uses of MS – for classification and identification of 
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bacteria, DNA analysis, screening and diagnostic research, multiplex genotyping, 
sequencing, genomics research, hospital infection control and quality control testing – have 
already been reviewed [5–8].
MS for detecting analytes as biomarkers was previously not readily appreciated, especially 
for NA identification. That particular use did not merit a mention in a thorough review of the 
state of the molecular diagnostics of infectious diseases published not long ago and which 
included all basic technologies and procedures used in clinical laboratories performing 
molecular diagnostics [9]. In proteomic studies, however, MS quickly gained recognition as 
a ‘gold standard’ tool for the identification and analysis of individual proteins. Currently, 
however, MS is being applied far beyond its use for protein characterization to include other 
types of analytes, including NAs [5].
MS detection of diagnostic markers is rapid, taking only milliseconds to seconds. The 
preparation of the analyte is highly amenable to automation, which additionally broadens the 
field of possible applications. MS is easily adaptable to different scales of detection and 
applicable for low-, medium- and high-throughput clinical screening and diagnostic testing 
[10]. Sub-picomolar amounts of the analyte can be detected without fluorescence or 
radioactive isotope labeling or using antibodies or hybridization probes. It can be used to 
detect the material of interest directly [11] or after attaching an intermediate detector 
molecule, thus conferring high sensitivity to detection [12]. Direct detection significantly 
simplifies the MS diagnostic applications [10,13]. As a detection system for NAs, MS can be 
easily coupled with any widely available DNA amplification technique. These qualities, 
combined with the capability of multiplexing – that is, testing for different analytes at the 
same time – make MS particularly suitable for rapid molecular diagnostics in the clinical 
setting. MS is uniquely suited for supporting multiple diverse applications. The throughput 
and multiplexing capacity of MS help reduce the cost of testing.
MS principles & platforms as used for the detection of NAs
All MS applications are based on direct measurement of two intrinsic properties of the 
bioanalyte: molecular mass and charge. The mass spectrometer consists of three functional 
units. The first unit, the ion source, is used to ionize the analyte and transfer it to the gas 
phase. The second unit is the mass analyzer that serves to separate the ions by their mass-to-
charge ratio (m/z), which in turn defines their TOF. It can have various configurations that 
use a vacuum chamber and a static or dynamic magnetic/electric field to separate the ions. 
The third unit is a detector device, an electron multiplier or fast oscilloscope, which detects 
the ions.
There is a great variety of ionization methods using atmospheric pressure (spray), chemicals, 
electrons, heat, ions, atom bombardment and so on. Most ionization techniques that require 
chemical or electrical ionization are too energy rich and frequently result in unpredictable 
decomposition of the NA analyte. Softer ionization approaches that use electrospray device 
or matrix carrier and laser ion source, such as ESI [4] and MALDI [3], have solved this 
degradation problem and account for the majority of currently used ionization techniques. 
Additional issues arising when working with NAs, such as depurination or generation of salt 
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adducts, have been resolved by utilizing improved reagents and clean-up methods and by the 
discovery that ribonucleotides are more stable than deoxyribonucleotides [14].
ESI-MS
ESI-MS is a soft technique where the analyte is dissolved in organic solvent like methanol or 
acetonitrile, sometimes in combination with acetic acid, and then injected in a conductive 
capillary where high voltage is applied. This results in the emission of aerosols of charged 
droplets of the sample. The aerosol travels through sections of decreasing pressure, which 
leads to formation of gas-phase ions of the analyte. ESI is typically coupled with an 
automated autosampler in a well-plate format, injector and liquid chromatography, which 
controls the flow rate of sample delivery and buffers the zones between samples. The rate of 
sample detection is several minutes per sample. The analyzer/detector can be FTICR, which 
detects all generated ions simultaneously and differentiates them by their rotational 
frequency, which is then transformed into a specific mass reading or a micro-TOF. The 
FTICR detection has great accuracy and high resolution [15]. A schematic representation of 
the ESI-MS is shown in Figure 1.
After the revolutionary development of this soft ionization technique [4], in a short time 
span the process was utilized for the analysis of PCR-amplified DNA products [16] and the 
study of noncovalent molecular complexes, peptides, glycans and so on. Technological 
improvements in DNA fragment preparation led to the introduction by Ibis Biosciences of a 
novel platform T5000 for rapid identification of pathogens [17]. The process has medium- to 
high-throughput capability, and applies ESI-MS. In essence, it combines the accuracy and 
sensitivity of multilocus sequence typing with the speed, throughput and accuracy of MS.
MALDI-TOF MS
There are two major classes of matrix, ‘hot’ and ‘cool,’ for desorbing laser energy that can 
be used in MALDI-TOF MS. The hot matrices have higher desorption/ionization energy, 
which results in excessive fragmentation of the analytes, and thus are more suitable for 
detection of small RNA molecules. Cool matrices are used for larger oligonucleotides and 
cause little fragmentation. Commonly used matrices for RNA are a mix of 2,3,4- and 2,4,6-
trihydroxyacetophenone, and matrices for DNA are α-cyano-4-hydroxycinnamic, 2,5-
dihydroxybenzoic or 3-hydroxypicolinic acid [7]. The matrix is crystallized on a solid inert 
surface. The sample is then imbedded in the matrix by dispensing in nanoquantities and 
desorbed and ionized by short (3–4 ns) UV-laser or IR-laser pulse. The ions are accelerated 
by an electric field to the same kinetic energy and sent into a field-free drift flight vacuum 
tube where ions of different m/z values are separated from each other. The velocity of the 
ions depends only on the m/z – that is, heavier molecules travel at lower speed and thus 
reach the detector later. The detection of analytes from a single target spot can be 
accomplished in several seconds. For analysis of NAs, the TOF needed for the ionized 
analyte to reach the detector is recorded and used to derive the analyte mass. This method 
has resolution reaching 1 Da that allows for the discrimination of single nucleotides. A 
schematic representation of MALDI-TOF MS is shown in Figure 2.
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Both ESI-MS and MALDI-TOF MS, given the appropriate analyzer, are sensitive to small 
variations in the primary structure of NAs and are capable of discriminating between even 
single nucleotide differences. This capacity of MALDI-TOF MS was significantly improved 
with the development of better matrices; methods to eliminate adduct-forming agents and 
novel biochemistries [18]. The predominant current use of MALDI-TOF MS is in the fields 
of genotyping/SNP typing, methylation analysis, quantitative gene expression analysis and 
resequencing [19].
Pathogen detection & identification
The presence of certain phenotypic, biochemical or genetic characteristics has been used 
routinely in most clinical laboratories for identification and differentiation of microbes. 
Molecular diagnostics are based on the specific recovery and detection of certain genomic 
fragments. NA characterization techniques such as plasmid profiling, fragment length 
polymorphisms and PCR-based systems significantly improved the sensitivity, specificity 
and throughput of detection of microbial pathogens directly from clinical samples. 
Application of these techniques, however, is limited mostly to the detection of pathogens 
that are difficult to culture in vitro.
Sequence analysis of amplified microbial DNA allows for even more accurate 
characterization of pathogens. Molecular identification of bacteria and viruses is based on 
the significant sequence specificity of NAs in different organisms. The first applications of 
MS to molecular microbiological diagnostics were in detection of PCR products generated 
from genomic regions of pathogens. The pathogen specificity can be detected using the 
entire PCR fragment or site-specific cleavage products of the fragment. Many sensitive 
pathogen identification assays require amplification or a particular labeling of the signature 
molecule. Visualization or detection of the NA generally involves size separation or 
detection of the labeled probe. One of the first successful applications of both MALDITOF 
and ESI approaches were to characterize PCR amplicons of the cystic fibrosis 
transmembrane conductance regulator gene [16]. A similar assay principle was applied 
shortly after to the successful identification of immobilized PCR products of hepatitis B 
virus (HBV) obtained from serum, demonstrating that identification by MS is a fast and 
reliable method for pathogen detection [20].
Although the application to pathogen detection was particularly successful, the mere use of 
MS as a detection system in place of, for example, gel electrophoresis did not resonate with 
many researchers, mainly because of the seeming complexity of MS. It also coincided with 
the introduction of the real-time PCR, attractive with its ease of detection and quantification 
of PCR products [21], which took away for a while from the development of the MS 
applications to molecular diagnostics. However, MS not only surpasses electrophoresis in 
rapidity and sensitivity as a detection system, but allows for precise sizing of the molecule of 
interest and also provides information on nucleotide composition and charge. The 
temporarily neglected potential of MS was revived with the expanding need for development 
of higher throughput DNA analysis techniques and discovery of novel MS applications to 
molecular diagnostics beyond simple detection [22]. Yet another advantage of the MS 
platforms in general is that they allow for the simultaneous detection of multiple analytes. 
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Initially, MS methods were applied to the simultaneous detection of two bacterial pathogens 
[23], but further along came the multiplexed detection of human herpesviruses [24], human 
papillomaviruses (HPVs) [25] and variants of HBV [26].
Restriction fragment length polymorphism (RFLP) has also been a tool of choice for 
organism identification and detection of polymorphisms. Coupling RFLP, illustrated in 
Figure 3A, to MS produced especially efficient technology. Replacement of gel 
electrophoresis with MS for the separation of restriction fragments generated by RFLP was 
recently implemented for the detection of avian influenza viruses [27,28], genotyping of 
hepatitis C virus (HCV) [29] and detection of drug-resistant HBV variants [30]. The 
application of MS to analyzing the products of robust and sensitive NA technologies such as 
real-time PCR, RFLP or uracil DNA glycosylation improved identification of pathogens not 
merely because of the high-throughput capability of MS, but also because a new layer of 
accurate molecular information could be acquired.
Phylogenetic analysis of the 16S rDNA-gene sequence for the purpose of microbial 
identification has been considered a gold standard for over 20 years. Specific and 
reproducible molecular identification of Mycobacterium spp. was successfully achieved by 
base-specific cleavage of transcripts generated from 16S rDNA amplicons and MS 
separation of the resulting RNA fragments [31]. The new biosensor technology, triangulation 
identification genetic evaluation of biological risks (TIGER) [32], on the Ibis T5000 
platform was developed using ESI-MS. The molecular element of the test starts with 16S 
RNA as a base, and adds on the use of broad-range primers aimed at essential housekeeping 
genes from bacterial, fungal and protozoan pathogens or specific genomic regions of viruses. 
The targeted PCR amplicons are mixed with an internal calibrant amplicon of known 
concentration. Analysis is accomplished by matching the base composition of the detected 
fragments to a database of composition signatures, predetermined for every particular 
organism. As the different isolates of each pathogen differ slightly, the system handles the 
diversity by building the probability space from the composition constraints for each species. 
By a stepwise process of joint maximum likelihood and maximum likelihood clustering, the 
sample is assigned an organism ID and its abundance estimated. The algorithm involves 
more than one locus per pathogen. The redundancy affords as high an accuracy of pathogen 
identification as can be achieved by direct sequencing [15,32]. PLEX-ID is the more current 
version of the technology and it expands to viral detection [33]. A schematic representation 
of the test and the process pipeline are shown in Figure 4.
TIGER found many applications including detection and identification of Acinetobacter 
species [34], a novel coronavirus responsible for the recent SARS outbreak [35] and 
alphaviruses [36]. The same platform has been applied very successfully to global 
surveillance of emerging influenza viruses [27,37], quantitative detection of orthopoxviruses 
[38] and vector-borne flaviviruses [39] and characterization of zoonotic influenza viruses 
prior to pandemic spread [40]. The more recent modification of the platform with focus on 
viral typing, PLEX-ID, is now certified for in vitro diagnostics in Europe.
Although identification of pathogens using MS is usually accomplished by direct detection 
of the pathogen-specific NAs, alternative approaches based on using cleavable mass-tags 
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have been recently developed for indirect detection of pathogens [41,42]. Avoiding many 
limitations of the direct detection of NAs, such as the aforementioned fragmentation and salt 
adduct formation, the mass-tag approaches offer greater robustness and sensitivity of 
detection as well as ease of multiplexing. The indirect detection methods take advantage of 
the MS ability to detect and differentiate among fairly small molecular tags that can be 
cleaved from NAs to identify a specific target that may itself not be amenable to MS because 
of size constraints and is illustrated in Figure 3B. A recent development is based on using a 
photocleavable linker with tagged molecules for PCR and ELISA quantification coupled to 
MS [43]. However, the effective application of the mass-tag methods to the multiplex 
detection of pathogens is still awaiting further validation.
DNA sequencing
Nothing else showcases the capacity of MS to accurately identify single-point nucleotide 
differences as its application to DNA sequencing. MALDI-TOF MS has been applied to 
sequencing of short DNA fragments for over 25 years. MALDI-TOF MS of the products 
from base-specific, dideoxynucleotide chain-termination DNA-sequencing reactions 
catalyzed by modified T7 DNA polymerase allows reading of short stretches of sequence 
(45 nucleotides in length) with as little as 5 fmol material [44]. Another early success was 
recorded with 63-nucleotide long sequencing ladders generated on an immobilized synthetic 
template for which the resolved sequence included the primer. In essence, this is a solid-
phase Sanger DNA sequencing followed by detection of the extended products by MALDI-
TOF MS [45], as illustrated in Figure 3C. The sequencing capacity of that approach is 
limited to the range of possible mass-size acquisition window; that is, the range of mass 
sizes of DNA products that can be effectively resolved by MS. In addition, the length of 
sequences is restricted by the presence of primer in each extension DNA product.
Thus, coupling MS to Sanger DNA sequencing seemed to be impractical, albeit applicable, 
for de novo sequencing. However, it is particularly suitable for comparative DNA 
sequencing aiming at the detection of one or very few mutations in short genomic fragments 
or for the resolution of hard-to-sequence fragments that could not be separated reliably in 
the standard electrophoretic manner due to compression or false termination. MS is quite 
suitable as a fast, high-fidelity alternative to conventional sequencing procedures for which 
high-throughput automated screening for mutations is needed [14].
The aforementioned applications exemplified the feasibility of DNA sequencing using MS; 
however, they did not take advantage of the MS capacity for accurate resolution of complex 
molecular mixtures and, therefore, could not compete successfully with gel-based 
technologies. MS, however, is more sensitive to the nucleotide composition of NAs than 
electrophoresis as used in conventional sequencing, thus allowing for a greater resolution of 
short DNA or RNA fragments and providing an opportunity for development of novel MS 
applications for sequencing using base-specific cleavage of target DNA. For these 
applications, many oligonucleotide-size fragments generated by the cleavage may have the 
same length but different nucleotide compositions. Separation of such fragments presents a 
significant challenge for gel electrophoresis-based technologies, but the fine resolution 
afforded by MS allows for accurate identification of these fragments.
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The critical improvement of the molecular technique that allowed resequencing of fragments 
of significant size came less than a decade ago with the introduction of the transcription-
coupled base-specific RNase A cleavage [46]. The technology uses a PCR amplicon 
generated with gene-specific primers with one being flanked with T7- and the other with 
SP6-promoter regions. The amplicon is then subject to transcription by either T7 or SP6 
polymerase in the presence of all four nucleotides to obtain transcripts from both DNA 
strands. UTP or CTP are modified to prevent cleavage by RNase A. Each reaction is carried 
out isothermally where transcription and cleavage occur simultaneously. The products are 
resolved by MALDI-TOF MS, resulting in mass patterns that are matched automatically to 
in silico generated cleavage patterns of an appropriate reference-sequence set. A schematic 
representation of the process and a process pipeline are shown in Figures 3D & 5, 
respectively. Although this approach is somewhat inefficient for de novo sequencing, as it 
requires a substantial reference database and hence great computational power, it has 
numerous applications for resequencing, genotyping and mutation discovery.
A recent comprehensive review of the available DNA sequencing strategies covered six 
different approaches to sequencing, namely: dideoxynucleotide terminators, cyclic array, 
sequencing-by- hybridization, micro-electrophoresis, MS and nanopore sequencing [47]. It 
acknowledged the role of MS as a fine tool to address specific problems that cannot be 
resolved by other methods, especially in the area of direct RNA sequencing, resequencing 
and methylation analysis [48], but rightly argued that MS may not outcompete the next-
generation sequencing (NGS) approaches such as cyclic array (Roche, Illumina, Helicos, 
Applied Biosystems) and nanopore sequencing (Agilent, Oxford Nanopore Technologies, 
Noblegen) for de novo high-throughput applications.
Methylation
Methylation is a central epigenetic process, key to understanding pathogenesis and 
carcinogenesis; it has particular importance for gene regulation and is strongly implicated in 
the development of cancer and the response to infectious agents [49]. There is an accepted 
relationship between DNA methylation, chromatin structure and human malignancies [50]. 
It has been proposed that the host uses chromatin methylation as a defense against DNA 
viruses, because most CpG sites in the host genomes are methylated so as to regulate gene 
expression and facilitate the recognition of pathogen-associated DNA [51]. Methylation has 
been identified as a host defense mechanism in the event of infection with HBV, and it has 
been demonstrated that the methylation of viral DNA leads to downregulation of the HBV 
gene expression [52].
The first assay for the analysis and precise quantification of methylation of CpG positions in 
simplex and multiplex reactions was based on MALDI-TOF MS [53]. The methylation 
assays are based on the same principle as the aforementioned resequencing assay; however, 
they require sodium bisulfate treatment of the DNA of interest prior to other enzymatic 
procedures. The treatment preferentially deaminates cytosine residues to uracil, leading to 
change of sequence. Comparison of treated and untreated samples that are then cleaved by 
RNase A reveals the number and location of methylated sites.
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Pathogen genotyping
Genotyping of infectious agents is needed to study the agent’s epidemiology, to detect 
transmission and to make clinical decisions on the appropriate course of treatment [54]. 
Certain viral genotypes have been associated with development of more aggressive acute or 
chronic disease or development of cancer. Different strategies for strain discrimination like 
hybridization, ligation, cleavage and primer extension (most popular) have been combined 
with MS to detect genotypes [7].
A large body of data has been presented showing the reliability of discriminating sequences 
differing at a single nucleotide position, so permitting rapid characterization of both cultured 
and uncultured bacteria [55]. Genotype identification has been achieved by MS separation of 
DNA fragments generated from 16S PCR products by base-specific DNA degradation with 
uracil DNA glycosylation in combination with alkaline treatment. Strategies based on the 
base-specific degradation of DNA and RNA molecules were proven to be very sensitive to 
minor variation in nucleotide sequence among genetically related organisms [10,46,55]. 
Specific and reproducible typing of Mycobacterium spp. has been achieved successfully by 
coupling such molecular approaches to MS analysis; for example, highly multiplexed 
spoligotyping [56] and multilocus sequence typing [57].
Examples of MALDI-TOF MS for viral typing include an efficient primer extension assay 
based on the 5´-untranslated region developed for the identification of the 11 major 
genotypes and over 70 subtypes of HCV [58]. An alternative HCV genotyping assay is 
based on restriction fragment mass polymorphism (RFMP) analysis of the 5´-untranslated 
region. This assay has the practical advantage of being capable of identifying mixed viral 
genotypes present at concentrations as low as 0.5% and accurately determining their relative 
abundance without the need for genetic cloning [59]. An improved RFMP-based MALDI-
TOF MS assay mediated by the use of artificially introduced type IIS restriction enzyme 
sites has been developed for high-resolution genotyping of HPV. The assay was shown to 
successfully identify at least 74 different HPV genotypes [60].
The MassARRAY® was developed specifically for assessing genetic polymorphisms and 
can be used for the analysis of SNPs, insertions, deletions and repeats [61]. It uses detection 
of mass differences between a specific probe and single nucleotide extension products of 
that probe; the unique mass of the extended oligonucleotide is identified by MALDI-TOF 
MS (Figure 3E) and the process pipeline shown in Figure 5. The MassARRAY assay is able 
to reliably distinguish 0.1–0.01% differences between masses of short oligonucleotides in a 
detection window of 3800–12,000 Da. The assay detects minority alleles that present at only 
2% in DNA mixture. It is readily amenable to multiplexing and suitable for high-throughput 
genotyping. A sequence-based high-throughput method for the MassARRAY platform has 
been developed for the detection of 14 oncogenic HPV genotypes in multiplex PCR 
products. This approach was shown to outperform the reverse dot-blot hybridization in 
sensitivity, cost and turnaround time [62]. A successful assay for typing influenza viruses 
was developed using the ESI-MS T5000 platform [37].
Viruses present a particular challenge to typing assays because their replication machinery 
generates a high error rate, resulting in the extensive genetic variability of the intra- and 
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interhost viral populations. One of the first HBV genotyping assays adapted to MS was 
based on MALDI-TOF [63]. Recently, an improved approach to HBV genotyping was 
designed and implemented using the MassARRAY platform. The assay did not only detect 
genotypes accurately but was capable of identifying new HBV variants [64]. Genotyping 
was achieved by comparison of mass patterns experimentally obtained from the S gene of 
the tested strain to computer-simulated HBV variants with known genotype. Multiple 
parameters such as viral titer, genotype, heterogeneity, quality of PCR products and MS 
patterns were carefully evaluated in the design and testing of this assay. The quality of PCR 
product was found to be the only property that significantly affected the accuracy of HBV 
genotyping. Assay outcomes had complete concordance with the gold-standard sequence 
results. Although it was not capable of specifying minor HBV genotypes in mixed-genotype 
infection cases, the predominant genotype was never reported erroneously. Given the 
sufficient quality of PCR products, MS patterns with low matching score to the reference 
dataset indicated either the mixed-genotype infection or presence of new HBV variants. The 
flexible assay design allowed for a rapid adjustment to the detection of such new HBV 
variants by simply updating the reference dataset with these variants. Highly amenable to 
automation and high-throughput detection, this assay was commended for molecular 
surveillance of HBV infection as a low-cost alternative to the sequence-based methods [65].
Polymorphic sites & intra-host diversity
By the middle of the last decade, there was already a clear recognition that NA analysis by 
MS, in particular by MALDI-TOF MS, would emerge in the post-genome sequencing era as 
a versatile tool for viral typing, analysis of polymorphisms, sequencing, DNA methylation 
and RNA expression in a multiplex manner [7]. Identifying genetic diversity by means of 
detection of SNP instead of using a complete genome sequence scale is a very practical 
approach to identifying important genetic variants of pathogens (Figure 3E). MS is 
especially applicable to SNP analysis [61]. After the introduction of the base-specific 
cleavage concept [46], MS-based SNP analysis has found many fields for its application 
[7,66,67]. Multilocus genotyping in massively parallel tests is becoming a preferred strategy 
for the accurate and high-throughput human SNP detection [18,68], with MALDI-TOF MS 
being among the most powerful and widely used technological platforms. A major 
advantage of the MS application to molecular diagnostics originates from the unmatched 
capacity of MS to decode reliably the composition of complex mixtures of short DNA or 
RNA fragments, and its amenability to high-throughput analysis of such mixtures. The base-
specific degradation of PCR products has been extensively used for the specific detection of 
pathogens, pathogen genotypes and even minor genetic variations associated, for example, 
with drug resistance [69]. Resolution of products of the base-specific degradation by MS 
dramatically improves the speed, throughput and accuracy of detection [11,70].
Many viruses generate genetic variants spontaneously or under selective pressure of, for 
example, antiviral therapy [71,72]. Such variations can confer drug resistance or affect virus 
replication capacity, resulting in therapeutic failure. Automated MALDI-TOF MS was used 
for detection of 60 different known mutations in the reverse transcriptase gene, precore 
promoter and basal core promoter of the HBV genome. MS and direct sequencing showed 
only 0.1% discordance in variant calls; however, MS was able to detect twice as many minor 
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variants as direct sequencing while achieving close to full automation and more sensitive 
detection [26]. The RFMP-based MALDI-TOF MS approach was developed for the 
detection of mutations in the HBV polymerase, particularly in the YMDD motif. The assay 
was found to be sufficiently sensitive for the early detection of HBV-breakthrough infections 
in patients on therapeutic treatment with polymerase inhibitors [73]. A similar approach 
showed a remarkable ability in detecting as few as 100 copies of the HBV genome. It 
correctly identified several known viral variants, finding minority intra-host viral variants 
undetectable by other tested methods and estimating the relative abundance of the variants 
[74]. The RFMP-based MALDITOF assay has been evaluated in comparison to the 
commercially available INNO-LiPA HBV DR assay based on reverse hybridization line-
probe technology. The MS assay provided the greater detection sensitivity for the mutations 
of interest and identified additional minor intra-host viral subpopulations [75], heralding its 
clinical applicability.
Mechanisms of viral persistence continue to be the subject of investigation. An important 
aspect of chronic HCV infection is the quasispecies nature of viral populations, which has 
been particularly well documented in the hypervariable region 1 (HVR1) of the E2 
glycoprotein. Recent studies showed that characterization of the quasispecies diversity at the 
amino acid level could help to predict the outcome of HCV infection. The accurate 
characterization of HCV quasispecies requires cloning of PCR products, followed by 
sequencing of many clones. A method based on in vitro translation of PCR amplicons, 
followed by MS analysis of the resulting peptide mix was developed for characterization of 
HCV diversity in infected hosts [76]. The assay was shown to detect the weekly HVR1 
changes in the HCV-infected chimpanzee, which coincided with emergence of neutralizing 
antibodies [77]. Using both a MS-based method and the conventional method of cloning and 
sequencing, weekly changes of the HVR1 quasispecies in the HCV-infected chimpanzee 
could be followed and detected with great sensitivity.
Analysis of genetic heterogeneity of viral populations was found to be especially important 
for evaluation of safety of live-attenuated vaccines, since the presence of even small 
quantities of mutants or revertants may be associated with incomplete or unstable 
attenuation of viral strains. However, assessment of the presence of such mutants in a viral 
population is laborious. MS provides a rapid and accurate platform for such assessment. 
Recently, DNA MassARRAY was used for evaluation of genetic variation in live-attenuated 
mumps virus vaccine [78]. A strong correlation with estimates of variation made using 
restriction enzyme cleavage analysis of PCR fragments indicated the utility of MALDI-TOF 
MS for routine quality control of live viral vaccines, assessment of their genetic stability and 
quantitative monitoring of genetic variations.
Genetic relatedness & transmission detection
Transmission is a fundamental viral property, essential for dissemination of infection and 
disease. As such, it is key to surveillance of infectious diseases. Molecular detection of 
transmissions can be a complex task. It involves not only identification of the virus, but 
assessment of the genetic association among its variants. The major assumption of the 
genome-based detection of transmissions is that the genetic composition of the viral strain 
Ganova-Raeva and Khudyakov Page 10
Expert Rev Mol Diagn. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
that has been passed from one patient to another remains approximately ‘identical’. 
Detection of transmission, especially when it pertains to viruses, can often present a 
challenge, in particular when the agent concerned causes chronic disease – that is, the agent 
has the opportunity to accumulate multiple mutations.
Genetic heterogeneity is a hallmark of many viruses. HCV, for example, exists as multiple 
variants or quasispecies in each infected individual. Consensus sequencing of the HCV 
HVR1 or NS5A gene, or also NS5b, is commonly applied to determine genetic relatedness 
among HCV strains and to identify HCV transmission [79]. However, consensus sequence 
cannot adequately represent the entire HCV population present in the host, particularly in 
chronically infected patients where the viral genetic heterogeneity can be extensive.
Accurate identification of HCV strains involved in transmission can be achieved by 
matching the genetic compositions of viral populations sampled from the infected hosts. 
Since HVR1 is one of the most variable regions of the HCV genome, analysis of intra-host 
HVR1 variants is frequently used for identification and tracking of HCV transmission. Such 
analysis involves: separation of individual HVR1 variants either by genetic cloning of PCR 
amplicons or by PCR cloning using end point limiting-dilution of cDNA and sequencing of 
these variants [80]. NGS technologies couple the separation of genetic variants with 
sequencing, thus significantly simplifying the assessment of viral heterogeneity. However, 
the high rate of sequencing errors generated per DNA read and problematic representation of 
intra-host viral heterogeneity are potential hindrances to adopting NGS approaches to the 
detection of transmissions.
Recently, MALDI-TOF MS was explored for identification of HCV transmission [81]. MS 
profiles (MSPs) generated by base-specific cleavage of RNA transcripts derived from PCR 
fragments were used as source of information about the nucleotide sequence and structure of 
the intra-host viral population. The assay detected patterns of short RNA fragments or k-
mers. It was found that the k-mer structure of the MS data closely reflects the heterogeneity 
of viral populations. Since the genetic distances estimated using MSPs are affected by 
sequence heterogeneity and composition of intra-host HCV populations [82], MSPs were 
shown to be highly applicable to evaluating phylogenetic relationships among HCV strains. 
The analyses revealed that there is a fundamental similarity between MSP- and sequence-
based distances, making them suitable for the genetic detection of transmissions. The 
separation between MSP distances among genetically related and unrelated cases is clear 
and permitted discrimination of the HCV variants involved in the outbreaks. Such detection 
of transmission does not require complete assessment of phylogenetic relationships among 
the HCV variants and, therefore, can be achieved using a threshold and visualized using 
simple linkage graphs. The MSP-based detection of HCV transmissions matched the 
accuracy of sequence-based methods, paving the way for the application of MS to molecular 
surveillance of viral hepatitis [65].
Expert commentary
The fourth Annual Next Generations Diagnostics Summit held in Washington, DC, USA, in 
August 2012 included a session on molecular diagnostics for infectious disease, dedicated to 
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emerging and novel technologies. The summit emphasized the important potential role of 
MS for the clinic, recognized that the technological discoveries that enabled the finding of 
multiple biomarkers have yet to be translated to the clinical practice and encouraged 
clinicians and scientists to adopt technologies that identify not only pathogens alone but can 
also reveal resistance determinants present in the pathogens.
During the last decade, MS has emerged as a rapid, cost-effective and highly reproducible 
technique with multiple versatile applications to molecular diagnostics. Many studies 
demonstrated efficient applications of MS to the detection of viral pathogens with ESI-MS 
being especially successful in these applications [32]. Although there are competing 
technologies like microchip and microarray in the field, MS stands on its own. The major 
advantages of MS over other competing technologies are most evident when related to 
investigating parameters of viral infections that require assessment of genetic heterogeneity; 
for example, detection of mutations, prediction of outcome of therapeutic treatment, and 
detection of transmissions and genetic relatedness among viral variants. Although there are 
other technologies such as NGS that can assess the same parameters efficiently, MS is 
unprecedented in its simplicity in providing dense and accurate genetic information directly 
associated with the variability parameters of viral infections.
When properly matched with molecular technologies compatible with the mass detection 
range – for example, base-specific cleavage of DNA or RNA molecules – MS provides an 
unparalleled capacity for cost-effective and high-throughput detection of genetic markers 
crucial for molecular surveillance of viral infections and disease as well as for patient 
management, with MALDI-TOF MS being especially useful in generating information-
dense data on the genetic composition of intrahost viral populations. It appears that 
degrading long NA molecules into short k-mers produces MS patterns that accurately reflect 
not only the primary structure but also the diversity and frequency of intra-host viral 
variants, as represented by PCR fragments amplified from viral genomes [46]. Viral genetic 
heterogeneity has long been found to be associated with outcomes of infection or therapy 
treatment. Currently, genetic heterogeneity is assessed using NGS, genetic cloning or limited 
dilution followed by sequencing. Although DNA sequencing using MS is not as efficient as 
NGS, analysis of MS patterns directly without conversion into sequences seemed to provide 
adequate estimates of genetic composition of viral populations and can be used to measure 
genetic relatedness among viral strains and detect viral transmissions [81,82]. However, MS-
generated data have structure, which is significantly different from sequences, and, 
therefore, it requires different computational and mathematical approaches for extraction of 
information relevant to physicians for patient management and public health practitioners for 
implementation and development of surveillance and prevention activities.
Five-year view
Application of MS to molecular diagnostics has become a very dynamic area of research 
with significant implications for medicine and public health. The most advanced 
developments have been generated by specific matching of molecular techniques with two 
major MS platforms: ESI and MALDI-TOF. MS as a detection system is most suited for the 
identification of complex genetic markers without invoking sequences. It can be envisioned 
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that the future development of MS-based molecular diagnostics will be linked to novel 
methods of extracting clinically and epidemiologically relevant information such as disease 
severity, drug resistance, vaccine escape and transmission from the genetic markers using 
specifically designed computational and mathematical models [83,84]. An important aspect 
of the MS technology will be the potential of its application to the rapid detection of 
microbes causing hospital infection [85]. If coupled with appropriate rapid and sensitive 
technologies for the diagnosis of preventable infections, MS can also have impact in the 
areas of quality control of sterile blood products and food safety [86]. Integration of 
molecular and computational approaches with MS should produce diagnostic assays for 
broad, routine application in public health and clinical practice.
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Key issues
• During the last decade, mass spectrometry (MS) has emerged as a rapid, cost-
effective and highly reproducible technique with multiple versatile 
applications to molecular diagnostics.
• MALDI and ESI are two major platforms for application of MS to molecular 
diagnostics.
• ESI-MS is especially efficient in detection of viral pathogens.
• MALDI-TOF is most efficient in assessment of viral and clinical factors 
associated with genetic heterogeneity of viral pathogens; for example, 
detection of specific mutations, prediction of outcome of therapeutic 
treatment, detection of transmissions, identification of genotypes and 
assessment of fine genetic relatedness among viral variants.
• MS is unprecedented in its efficacy of providing dense and accurate genetic 
information directly associated with clinical parameters of viral infections, 
thus successfully competing with such powerful technologies as next-
generation sequencing.
• The structure of the MS-generated data is significantly different from 
sequences and presents one of the major challenges to application of MS to 
molecular diagnostics.
• Future developments in the MS-based molecular diagnostics of viral 
infections are contingent on the successful matching between MS and 
molecular technologies, and application of computational approaches to 
identification of complex genetic markers from MS patterns directly.
• Integration of molecular and computational approaches with MS should 
produce diagnostic assays for broad, routine application in public health and 
clinical practice.
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Figure 1. Basic configuration of an ESI mass spectrometer for use in nucleic acid analysis
LC: Liquid chromatography; MS: Mass spectrometry.
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Figure 2. Basic configuration of a MALDI mass spectrometer for use in nucleic acid analysis
MS: Mass spectrometry.
Ganova-Raeva and Khudyakov Page 20
Expert Rev Mol Diagn. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Biochemical processes for comprehensive molecular analysis of specific gene targets as 
applied to analysis by mass spectrometry
(A) Restriction fragment length polymorphism – the complexity of large target molecules is 
reduced by enzymatic cleavage at predetermined sites, the resulting small molecules are 
analyzed by MS and the obtained mass patterns are used to infer organism identification. (B) 
Mass-tag multiplexing – each target is detected by a probe tagged by a cleavable small 
molecule, unused probes are removed/washed, the tags of the used probes are cleaved and 
used for detection by MS; detected tags indicate presence of the target of interest. (C) 
Generation of sequence ladder in the presence of one specific primer, regular nucleotides, 
dideoxynucleotides and polymerase, resulting in random termination of the fragments at any 
and all positions, allowing the discrimination of two fragments by one added nucleotide. (D) 
Sequencing by transcription with T6 and SP6 polymerases, coupled to RNase A single base-
specific cleavage. The process queries both strands of each amplicon of interest. The 
resulting mass fingerprint contains information about all four nucleotides and is used to 
derive the fragment’s sequence, genotype and heterogeneity and to discover new mutations 
by in silico pattern comparison to a comprehensive reference set. (E) SNP identification by 
multiplex PCR. Each product is then queried by a specific probe designed immediately 
upstream from a SNP of interest and then extended in the presence of ddNTP mix. The 
resulting extended probes present a mass signature that identifies the SNP sequence. 
Depending on the assay design (e.g., T5000) the multiplex product could be used directly for 
MS with the resulting mass patterns used for organism identification.
MS: Mass spectrometry; SAP: Shrimp alkaline phosphatase.
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Figure 4. Process pipeline for multiplex pathogen detection and identification by nucleic acid 
testing on an ESI platform
(A) Processes that are performed off the MS platform. (B) Processes that are executed on the 
MS platform.
MS: Mass spectrometry; NA: Nucleic acid.
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Figure 5. Process pipeline for multiplex single nucleotide polymorphism detection/identification 
and nucleic acid sequencing by testing on a MALDI-TOF platform
The top panel of A and B processes are performed off the MS platform, and then followed 
by acquisition executed on the MS platform. (A) Process line provides multiplexed SNP 
detection and identification. (B) Process line provides sequencing information. The 
estimated samples/hour refers to the capacity of the MS.
MS: Mass spectrometry; NA: Nucleic acid.
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